|
|
|
|
Board
Peter D. Parker
Chairman of the Board
Mr. Parker is currently President of BioInnovation, LLC, a provider of services and capital to Life Sciences start-ups. From 2006-2010 he was President and CEO of Cequent Pharmaceuticals (sold to Marina Biotech (NSDQ: MRNA) July, 2010). Before Cequent, Mr. Parker was a General Partner at Ampersand Ventures for 18 years focusing on the firm's Life Sciences activities. He has served as a director of numerous companies including ACLARA Biosciences, Tomah Products, VITEX, Magellan Biosciences, Dynex, Castlewood Surgical and Pentose Pharmaceuticals and as Chairman of Alexis, NOVEX, CoPharma, Huntington Laboratories, Protein Ingredient Technologies, Cyclis Pharmaceuticals, Nanodyne, Panacos Pharmaceuticals, AC Tech, BioEssences and TekCel. Prior to Ampersand, Mr. Parker spent fourteen years at AMAX, Inc. He holds B.S. and M.S. degrees from Columbia University.
Susan Hertzberg
Chief Executive Officer
Ms. Hertzberg has extensive laboratory medicine and diagnostics experience. Prior to joining Boston Heart Lab, Ms. Hertzberg was President and CEO of Ipsogen Inc., a molecular oncology products and services business focused on blood and breast cancers.
Susan spent much of her career at Quest Diagnostics, the nation's leading provider of laboratory services, where she held executive positions in Purchasing and Materials Management, Sales, Marketing and Payor Contracting. She has also worked in Diagnostics, at Abbott Labs and in Managed Care for Oxford Health Plans.
Susan holds a B.A. degree in psychology from Clemson University and a M.B.A. from Columbia University. She serves on the Board of Theracare, a private special educational services business.
Alice Limkakeng
Principal Bain Capital Ventures
Ms. Limkakeng joined Bain Capital Ventures in 2008. Prior to joining Bain Capital Ventures, Ms. Limkakeng was the Eastern U.S. sales manager for the LATITUDE division of Guidant Corporation, a leading medical device company, (acquired by Boston Scientific). In her six years at Guidant, Ms. Limkakeng held various roles in sales management, marketing and direct sales where she built and led teams to launch new remote patient management technology and implantable medical device products. Prior to Guidant, Ms. Limkakeng worked at Behrman Capital in New York City executing late stage venture and growth equity investments, primarily in health care. Earlier in her career, Ms. Limkakeng worked in investment banking advising on M&A transactions at James D. Wolfensohn & Co. and was a strategy consultant at Marakon Associates.
Jeff Crisan
Managing Director Bain Capital Ventures
Mr. Crisan joined Bain Capital Ventures in 2002 after working in Bain Capital's Private Equity group since 1998. Mr. Crisan focuses on healthcare, education, and technology investments, including healthcare services, healthcare IT, for-profit education, software, and technology-enabled business services. While at Bain Capital, Mr. Crisan focused primarily on technology and healthcare investments. Prior to Bain Capital, Mr. Crisan was a consultant with Bain & Company.
Ernst J. Schaefer, MD
Chief Medical Officer
Dr. Schaefer is Co-Founder and Chief Medical Officer of Boston Heart Lab. He and Dr. Asztalos (see below) have developed our company’s proprietary technology to measure HDL particles and developed the revolutionary new method to use HDL particle concentrations as a much more effective predictor for cardiovascular disease (CVD).
Dr. Schaefer is a distinguished professor at the Tufts University School of Medicine and the Friedman School of Nutrition Science and Policy at Tufts University.
He received the J.D. Lane Award of the U.S. Public Health Service (1981) and the Irvine H. Page Arteriosclerosis Research Award from the American Heart Association (1981) for defining the metabolic defect in Tangier disease and describing two new genetic disorders apoA-I/C-III/A-IV and apoE deficiency characterized by severe lipoprotein abnormalities and premature heart disease. Further did Dr. Schaefer received the Saul Horowitz Research Award from Mt. Sinai School of Medicine (1989), Oliver Smith Awards of Tufts-New England Medical Center for Patient Care (1999, 2001, 2003), the E.V. McCollum Research Award of the American Society for Clinical Nutrition (2000), and a Distinguished Faculty Award from Tufts University (2001). Since 1997 he has been a member of Who’s Who in America, and in 2004 was named among America’s Top Physicians by the Consumers Research Council of America.
Dr. Schaefer is an author or co-author of over 400 publications and served on the first and second adult treatment panels of the National Cholesterol Education Program of the National Institutes of Health, on the Nutrition Study Section and as chairman of the Metabolism Study Section of the NIH, and the Nutrition Committee of the American Heart Association. Since 1997 Dr. Schaefer has been the U.S. editor of the journal Atherosclerosis, the official journal of the European Atherosclerosis Society, and also serves on the Clinical Research Review Committee and Study Section of the NIH.
Mike Snyder
Chairman of the Hospital Laboratory at UMass Memorial Hospital
Mike Snyder is the Hospital Laboratory Chairman and Chief of Clinical Pathology of the UMass Memorial Hospital in Worcester, MA. He also serves as Professor of Medicine and Pathology at the UMass Medical School. Mike brings over 40 years of practical experience in growing commercial labs and was awarded the Outstanding Lab Director Reward of the War College in 1998. He trained at UCLA and the Mass General and graduated from the Chicago Medical School.
|
|
|
|
|
 |
 |
|
 |
 |
|
